⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19951622 | 1.00 | — | — | |
| SCHEMBL30828786 | 1.00 | — | — | |
| SCHEMBL245466 | 1.00 | — | — | |
| SCHEMBL4146707 | 1.00 | — | — | |
| SCHEMBL417278 | 1.00 | — | — | |
| SCHEMBL25527642 | 1.00 | — | — | |
| SCHEMBL7771659 | 1.00 | — | — | |
| Ammonia Solution, Strong SCHEMBL25431321 | 0.97 | — | — | |
| Iodide SCHEMBL4974469 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2018586 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510032-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORP (US) | 2022-07-06 | — | — | EP | claimed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4371987-B9 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025215579-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4371987-B1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-12258346-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-20240287061-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| CN-115151252-B | Iron death inhibitor-diarylamine acetamides | 维泰瑞隆有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20170217918-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-03 | — | — | US | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| WO-2014128070-A1 | PYRROLO- AND PYRAZOLO-TRIAZOLODIAZEPINES AS BET-PROTEIN INHIBITORS FOR TREATING HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |